ACTG Publications

TitleAuthorsDateJournalIssueVolume
Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir.Crawford, Keith W ; Spritzler, John ; Kalayjian, Robert C ; Parsons, Teresa ; Landay, Alan ; Pollard, Richard ; Stocker, Vicki ; Lederman, Michael M ; Flexner, Charles ; AIDS Clinical Trials Protocol 5015 Team2010 JunAIDS Res Hum Retroviruses626
Antiretroviral therapies in women after single-dose nevirapine exposure.Lockman, Shahin ; Hughes, Michael D ; McIntyre, James ; Zheng, Yu ; Chipato, Tsungai ; Conradie, Francesca ; Sawe, Fred ; Asmelash, Aida ; Hosseinipour, Mina C ; Mohapi, Lerato ; Stringer, Elizabeth ; Mngqibisa, Rosie ; Siika, Abraham ; Atwine, Diana ; Hakim, James ; Shaffer, Douglas ; Kanyama, Cecilia ; Wools-Kaloustian, Kara ; Salata, Ro2010 Oct 14N Engl J Med16363
Class-sparing regimens for initial treatment of HIV-1 infection.Riddler, Sharon A ; Haubrich, Richard ; DiRienzo, A Gregory ; Peeples, Lynne ; Powderly, William G ; Klingman, Karin L ; Garren, Kevin W ; George, Tania ; Rooney, James F ; Brizz, Barbara ; Lalloo, Umesh G ; Murphy, Robert L ; Swindells, Susan ; Havlir, Diane ; Mellors, John W ; AIDS Clinical Trials Group Study A5142 Team2008 May 15N Engl J Med20358
Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial.Flexner, Charles ; Tierney, Camlin ; Gross, Robert ; Andrade, Adriana ; Lalama, Christina ; Eshleman, Susan H ; Aberg, Judith ; Sanne, Ian ; Parsons, Teresa ; Kashuba, Angela ; Rosenkranz, Susan L ; Kmack, Anne ; Ferguson, Elaine ; Dehlinger, Marjorie ; Mildvan, Donna ; ACTG A5073 Study Team2010 Apr 1Clin Infect Dis750
Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188.Vogler, Mary A ; Patterson, Kristine ; Kamemoto, Lori ; Park, Jeong-Gun ; Watts, Heather ; Aweeka, Francesca ; Klingman, Karin L ; Cohn, Susan E2010 DecJ Acquir Immune Defic Syndr455
Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.Torriani, Francesca J ; Komarow, Lauren ; Parker, Robert A ; Cotter, Bruno R ; Currier, Judith S ; Dubé, Michael P ; Fichtenbaum, Carl J ; Gerschenson, Mariana ; Mitchell, Carol K C ; Murphy, Robert L ; Squires, Kathleen ; Stein, James H ; ACTG 5152s Study Team2008 Aug 12J Am Coll Cardiol752
First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial.Ciaranello, Andrea L ; Lockman, Shahin ; Freedberg, Kenneth A ; Hughes, Michael ; Chu, Jennifer ; Currier, Judith ; Wood, Robin ; Holmes, Charles B ; Pillay, Sandy ; Conradie, Francesca ; McIntyre, James ; Losina, Elena ; Walensky, Rochelle P ; CEPAC-International and OCTANE Investigators2011 Feb 20AIDS425
Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application.Keil, Kim ; Hochreitter, Jill ; DiFrancesco, Robin ; Zingman, Barry S ; Reichman, Richard C ; Fischl, Margaret A ; Gripshover, Barbara ; Morse, Gene D2007 FebTher Drug Monit129
Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial.Gross, Robert ; Tierney, Camlin ; Andrade, Adriana ; Lalama, Christina ; Rosenkranz, Susan ; Eshleman, Susan H ; Flanigan, Timothy ; Santana, Jorge ; Salomon, Nadim ; Reisler, Ronald ; Wiggins, Ilene ; Hogg, Evelyn ; Flexner, Charles ; Mildvan, Donna ; AIDS Clinical Trials Group A5073 Study Team2009 Jul 13Arch Intern Med13169
Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110.Tebas, P ; Zhang, J ; Hafner, R ; Tashima, K ; Shevitz, A ; Yarasheski, K ; Berzins, B ; Owens, S ; Forand, J ; Evans, S ; Murphy, R2009 MayJ Antimicrob Chemother563
The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis.Gupta, Samir K ; Rosenkranz, Susan L ; Cramer, Yoninah S ; Koletar, Susan L ; Szczech, Lynda A ; Amorosa, Valerianna ; Hall, Stephen D2008 Oct 1AIDS1522
Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.Fischl, Margaret A ; Collier, Ann C ; Mukherjee, A Lisa ; Feinberg, Judith E ; Demeter, Lisa M ; Tebas, Pablo ; Giuliano, Marina ; Dehlinger, Marjorie ; Garren, Kevin ; Brizz, Barbara ; Bassett, Roland2007 Jan 30AIDS321
Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV.Collier, Ann C ; Tierney, Camlin ; Downey, Gerald F ; Eshleman, Susan H ; Kashuba, Angela ; Klingman, Karin ; Vergis, Emanuel N ; Pakes, Gary E ; Rooney, James F ; Rinehart, Alex ; Mellors, John W ; AIDS Clinical Trials Group Protocol A5143 Team2008 Mar-AprHIV Clin Trials29
Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).Tebas, Pablo ; Zhang, Jiameng ; Yarasheski, Kevin ; Evans, Scott ; Fischl, Margaret A ; Shevitz, Abby ; Feinberg, Judith ; Collier, Ann C ; Shikuma, Cecilia ; Brizz, Barbara ; Sattler, Fred ; AIDS Clinical Trials Group (ACTG)2007 Jun 1J Acquir Immune Defic Syndr245